Table 4.
Contribution of individual TNF-α and LT-α gene polymorphisms in CF associated liver disease
| TNF genes | Cirrhosis (total) | p* | p** | Cirrhosis (without PH) | p* | p** |
|---|---|---|---|---|---|---|
|
TNF-α-308GA–LT-α + 252AA |
1/13 (7.7%) |
0.061 |
0.018 |
0/13 |
0.028 |
0.016 |
|
TNF-α-308 G–LT- + 252AA |
31/97 (32%) |
— |
>0.1 |
25/97 (25.8%) |
— |
>0.1 |
|
TNF-α-308GA–LT- + 252AG |
13/29 (44.8%) |
>0.1 |
— |
9/29 (31.0%) |
>0.1 |
— |
|
TNF-α-308GG–LT- + 252AG |
5/37 (13.5%) |
0.023 |
0.005 |
4/37 (10.8%) |
0.045 |
0.041 |
|
TNF-α-308GG–LT- + 252GG together with |
2/12 (16.7%) |
>0.1 |
0.087 |
0/12 |
0.036 |
0.029 |
| TNF-α-308GA–LT- + 252GG |
Boldface shows the unfavorable genotype in term of CF associated liver disease progression.
PH, portal hypertension.
* comparison with TNF-α-308GG – LT-α + 252AA.
** comparison with TNF-α-308GA – LT-α + 252AG.